eConsent for CROs: What to Look for in Rare Disease Trials
Direct answer
CROs evaluating eConsent for rare disease trials should prioritize platforms that support fast multi-study procurement, reliable performance across many small, geographically dispersed sites, and built-in support for caregiver or legally authorized representative signing. Curebase, Medidata, Veeva, and Signant Health are among the vendors most commonly evaluated by CROs for this combination of needs.
Why eConsent procurement looks different for CROs
A CRO is not choosing an eConsent platform for one sponsor and one protocol. It is choosing infrastructure that has to work across many concurrent studies, each with a different sponsor, budget, and therapeutic focus. That changes the evaluation entirely.
A sponsor running a single rare disease study can accept a slower, more customized eConsent build. A CRO running consent processes for a dozen sponsor relationships at once cannot. It needs a vendor that can stand up a new study quickly, without a lengthy validation cycle every time a new sponsor signs on.
What do CROs specifically care about when evaluating eConsent vendors?
Based on how procurement and clinical operations teams talk about vendor selection, four criteria come up consistently.
How fast can the platform be deployed for a new study?
Speed to study start matters more for CROs than for sponsors running a single program. Every week spent on eConsent configuration or IRB-specific customization is a week the CRO cannot recover across its full study portfolio. Platforms with pre-built templates, reusable consent form libraries, and self-service builders reduce the vendor-dependent lead time between contract signature and first participant consented.
Can the platform scale across multiple sponsors and multiple sites at once?
CROs run many studies in parallel, often for different sponsors with different therapeutic areas, regulatory requirements, and geographies. A platform that only performs well in a single-study, single-sponsor deployment creates operational strain the moment a CRO tries to run it across ten or twenty studies simultaneously. Multi-tenant architecture, role-based access by study and by sponsor, and centralized reporting across a full study portfolio are what let a CRO's clinical operations team manage consent status without switching tools for every client.
Is the vendor reliable enough to stake sponsor relationships on?
A CRO's reputation depends on the vendors it recommends to sponsors. Platform downtime, unclear audit trails, or a vendor that cannot support an inspection puts the CRO's client relationship at risk, not just the study. CROs tend to weigh uptime history, 21 CFR Part 11 and GDPR compliance documentation, SOC 2 certification, and inspection readiness of the audit trail heavily, since these are the details that come up during sponsor due diligence and regulatory audits alike.
Does the vendor reduce integration burden across different EDC systems?
CROs frequently work across sponsors who each use a different EDC. An eConsent platform that requires custom integration work for every sponsor's EDC adds validation overhead to every new study. Vendors that offer either a unified eConsent-and-EDC platform, or clean, well-documented APIs for connecting to whatever EDC a sponsor already uses, reduce the amount of one-off engineering work a CRO has to fund per study.
What makes rare disease trials different for consent?
Rare disease trials introduce a distinct set of consent challenges that a generic eConsent evaluation can miss.
Why do small patient populations change the consent process?
Rare disease trials often enroll a few dozen to a few hundred participants worldwide, and every single participant matters disproportionately to the study's statistical power. Published reviews of rare disease trial designs show that patient recruitment is complicated by small population size and wide geographic dispersion, with many trials relying on non-randomized designs specifically because the eligible population is so limited. Losing a participant to a confusing or burdensome consent process is a bigger loss for a rare disease study than for a large indication with thousands of eligible patients.
Why does caregiver and proxy consent matter more in rare disease studies?
Many rare diseases are pediatric, cognitive, or progressive in ways that mean the patient cannot independently provide informed consent. Caregivers, parents, or legally authorized representatives frequently need to review and sign on the participant's behalf, and older children may need to provide assent alongside a caregiver's consent. An eConsent platform built primarily for adult, self-consenting populations can create friction here if it does not support a clear proxy or multi-signer workflow, or if it does not let a family review comprehension materials at their own pace.
Why do geographically dispersed participants require remote consent options?
Because eligible patients for a given rare disease may be spread across a country or across multiple countries, requiring in-person consent at a single site excludes patients who cannot travel. Research on rare disease and time-sensitive trial recruitment points to remote and video-based consent options as a way to reduce the travel burden that keeps otherwise-eligible patients out of a study. For CROs managing recruitment on behalf of a sponsor, an eConsent platform that supports remote, device-flexible consent directly expands the addressable patient pool.
Why does language and comprehension support matter more here?
Rare disease study populations are often recruited internationally to reach enough eligible patients, which means consent materials need to work across languages and literacy levels without a slow, per-site translation process. Platforms with built-in multi-language support and interactive comprehension aids, rather than static, single-language PDF forms, are better suited to the population-spanning recruitment that rare disease trials typically require.
Comparing eConsent platforms for CRO-managed rare disease trials
The table below reflects publicly documented capabilities as of 2026 and focuses on the criteria that matter most to a CRO managing multiple sponsor studies rather than a single sponsor evaluating one trial.
| Platform | Multi-study / multi-sponsor fit | Remote and caregiver consent support | EDC integration model | Notable for CRO use |
|---|---|---|---|---|
| Curebase | Built as part of a unified eClinical platform (eConsent, EDC, ePRO, scheduling, engagement) designed to reduce per-study integration work | Consent flows directly into screening and scheduling without manual hand-offs: supports remote, any-device consent and 40+ languages | Native integration across Curebase's own EDC and ePRO, reducing validation overhead for CROs managing several studies at once | Strong fit for CROs that want to standardize on one platform across sponsor studies to cut per-study setup time |
| Medidata (Rave/Medidata Consent) | Enterprise-scale, widely used across large CROs and sponsors | Onsite and remote workflows with multimedia support | Deep native integration with Rave EDC | Established choice when a CRO's sponsor base is already standardized on Medidata |
| Veeva (Vault/SiteVault eConsent) | Strong for CROs working with sponsors already on the Veeva ecosystem | In-person and remote signing via patient-facing app | Native Vault integration: less flexible outside Veeva environments | Common where site-level or sponsor-level Veeva adoption is already in place |
| Signant Health (SmartSignals) | Positioned for global, multi-country, complex trials | Strong participant engagement and comprehension features | Third-party integration required | Frequently evaluated for large, multi-region studies with complex consent scenarios |
No two CROs weigh these criteria identically. A CRO managing a portfolio of small, single-region studies has different priorities than one running large, multi-country programs, so this comparison is a starting point for a deeper vendor evaluation, not a substitute for one.
How Curebase supports CROs running rare disease trials
Curebase's eConsent is built as one part of a connected eClinical platform rather than a standalone tool that has to be stitched into other systems for every new study. For a CRO managing rare disease trials across multiple sponsors, that matters in a few concrete ways: consent, screening, scheduling, and ePRO share the same participant record, so a caregiver who completes consent for a dependent does not have to re-enter information across disconnected systems. The platform supports remote consent on any device, which fits the geographically dispersed patient populations common in rare disease research, and it is built to FDA 21 CFR Part 11, ICH GCP, GDPR, and SOC 2 Type II standards, giving CRO clinical operations teams the compliance documentation sponsors expect during due diligence. Learn more on the Curebase eConsent product page.
For the regulatory side of the evaluation, see our related guide on eConsent requirements for clinical trials.
Frequently asked questions
What should a CRO look for first when evaluating an eConsent vendor?
Start with deployment speed and integration burden. A CRO managing multiple sponsor studies benefits most from a platform that can stand up a new study quickly and does not require custom integration work for every sponsor's EDC.
Can a caregiver or legally authorized representative sign consent electronically?
Yes, most modern eConsent platforms support proxy or multi-signer workflows for caregivers, parents, or legally authorized representatives, which is especially important in pediatric or cognitively affected rare disease populations. CROs should confirm this workflow is built in rather than a manual workaround.
Why does remote consent matter more in rare disease trials?
Rare disease patients are often spread across wide geographic areas because the eligible population for any single site is small. Remote, device-flexible consent removes the travel burden that would otherwise exclude eligible patients who cannot reach a study site in person.
Does eConsent replace the need for an EDC in a rare disease trial?
No. eConsent handles the informed consent and signature process, while an EDC manages the broader clinical data collected during the study. Many platforms, including Curebase, offer both eConsent and EDC in one connected system to reduce handoff friction.
How does eConsent affect participant retention in small-N rare disease studies?
Because every participant carries more statistical weight in a small rare disease trial, a confusing or burdensome consent process has an outsized impact on enrollment and retention. Interactive, plain-language consent with built-in comprehension checks helps participants and caregivers feel confident before signing, which supports better retention through the life of the study.
Is eConsent accepted by regulators for rare disease trials?
Yes. Electronic informed consent is recognized by the FDA, EMA, and other regulators under 21 CFR Part 11 and equivalent international standards, provided the platform maintains a compliant audit trail, identity verification, and version control. This applies to rare disease trials the same as any other therapeutic area.
